Banque Pictet & Cie SA Grows Position in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Banque Pictet & Cie SA grew its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 165.7% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,499 shares of the company's stock after buying an additional 3,429 shares during the quarter. Banque Pictet & Cie SA's holdings in BioNTech were worth $501,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its holdings in shares of BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock valued at $419,000 after purchasing an additional 150 shares in the last quarter. Jones Financial Companies Lllp increased its holdings in shares of BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after purchasing an additional 246 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of BioNTech by 39.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company's stock valued at $21,349,000 after purchasing an additional 53,319 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of BioNTech in the 4th quarter valued at about $584,000. Finally, Daiwa Securities Group Inc. increased its holdings in shares of BioNTech by 7.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock valued at $221,000 after purchasing an additional 128 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

BNTX has been the subject of a number of research analyst reports. The Goldman Sachs Group initiated coverage on shares of BioNTech in a report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price target for the company. Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Truist Financial restated a "buy" rating and set a $155.00 target price (up from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Leerink Partners set a $112.00 target price on shares of BioNTech in a report on Monday, June 2nd. Finally, Morgan Stanley set a $133.00 target price on shares of BioNTech and gave the company an "overweight" rating in a report on Thursday. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $137.91.

BioNTech Trading Down 1.7%

BioNTech stock traded down $1.89 during trading on Monday, reaching $111.00. The company had a trading volume of 441,497 shares, compared to its average volume of 941,534. BioNTech SE Sponsored ADR has a 12-month low of $76.53 and a 12-month high of $131.49. The stock's 50 day moving average price is $103.56 and its two-hundred day moving average price is $106.76. The firm has a market capitalization of $26.68 billion, a price-to-earnings ratio of -32.65 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.